Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Daiichi Sankyo Company, Limited
  6. News
  7. Summary
    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Daiichi Sankyo Company, Limited and AstraZeneca Announce Reduction of Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer

09/18/2021 | 09:05am EST

Daiichi Sankyo Company, Limited and AstraZeneca HER2 directed antibody drug conjugate (ADC), demonstrated superior progression-free survival (PFS) versus trastuzumab emtansine (T-DM1), a HER2 directed ADC currently approved to treat patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. Results were presented as the first late-breaking presentation (#LBA1) in the ESMO Presidential Symposium at theEuropean Society for Medical Oncology (#ESMO21) 2021 Virtual Congress. At a pre-specified interim analysis of DESTINY-Breast03, ENHERTU demonstrated a 72% reduction in the risk of disease progression or death compared to T-DM1 (hazard ratio [HR] = 0.28; 95% CI: 0.22-0.37; p=7.8x10-22). After 15.5 and 13.9 months of follow-up in the ENHERTU and T-DM1 arms respectively, the median PFS for patients treated with ENHERTU was not reached (95% CI: 18.5-NE) compared to 6.8 months for T-DM1 (95% CI: 5.6-8.2) as assessed by blinded independent central review (BICR). In the key secondary endpoint analysis of PFS assessed by investigators, patients treated with ENHERTU experienced a three-fold improvement in PFS of 25.1 months (95% CI: 22.1-NE) compared to 7.2 months (95% CI: 6.8-8.3) for T-DM1 (HR=0.26; 95% CI: 0.20-0.35; p=6.5x10-24). A consistent PFS benefit was observed in key subgroups of patients treated with ENHERTU, including those with a history of stable brain metastases. There was a strong trend towards improved overall survival (OS) with ENHERTU (HR=0.56; 95% CI: 0.36-0.86; p=0.007172), however, this analysis is not yet mature and is not statistically significant. Nearly all patients treated with ENHERTU were alive at one year (94.1%; 95% CI: 90.3-96.4) compared to 85.9% of patients treated with T-DM1 (95% CI: 80.9-89.7). Confirmed objective response rate (ORR) was more than doubled in the ENHERTU arm versus the T-DM1 arm (79.7%; n=208; 95% CI: 74.3-84.4) versus 34.2% (n=90; 95% CI: 28.5-40.3; p


ę S&P Capital IQ 2021
All news about DAIICHI SANKYO COMPANY, LIMITED
12/06Nikkei 225 Down 0.4% on Omicron Variant Concerns
MT
11/30Daiichi Sankyo Company, Limited Announces DESTINY-Breast11 Neoadjuvant Phase 3 Trial of..
CI
11/29Japanese drugmaker Daiichi Sankyo sets up subsidiary in Singapore
AQ
11/26Tepco finds melting of ice wall at Japan's Fukushima Daiichi plant
RE
11/18Daiichi Sankyo Announces Positive Topline Results from the Global Pivotal QuANTUM-First..
CI
11/05A decade on, Fukushima farmers fear nuclear-tainted water's impact on business
RE
11/03Trastuzumab Deruxtecan Type Ii Variation Application Validated by Ema for the Treatment..
CI
11/03Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment..
CI
11/01Daiichi Sankyo's Attributable Profit Gains in Fiscal Q2
MT
11/01Daiichi Sankyo Company, Limited Launches DELYTACT? Oncolytic Virus G47 in Japan
CI
More news
Analyst Recommendations on DAIICHI SANKYO COMPANY, LIMITED
More recommendations
Financials
Sales 2022 1 021 B 8 979 M 8 979 M
Net income 2022 64 911 M 571 M 571 M
Net cash 2022 625 B 5 495 M 5 495 M
P/E ratio 2022 79,4x
Yield 2022 1,00%
Capitalization 5 120 B 45 122 M 45 022 M
EV / Sales 2022 4,40x
EV / Sales 2023 4,14x
Nbr of Employees 16 033
Free-Float 97,6%
Chart DAIICHI SANKYO COMPANY, LIMITED
Duration : Period :
Daiichi Sankyo Company, Limited Technical Analysis Chart | 4568 | JP3475350009 | MarketScreener
Technical analysis trends DAIICHI SANKYO COMPANY, LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 2 671,00 JPY
Average target price 3 789,29 JPY
Spread / Average Target 41,9%
EPS Revisions
Managers and Directors
Sunao Manabe President, CEO & Representative Director
Hiroyuki Okuzawa CFO, Director, Executive Officer & Head-Management
Ken Takeshita Global Director-Research & Development
Noritaka Uji Independent Outside Director
Tsuguya Fukui Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
DAIICHI SANKYO COMPANY, LIMITED-24.44%45 122
JOHNSON & JOHNSON3.53%428 955
ROCHE HOLDING AG17.23%322 390
PFIZER, INC.44.09%288 950
NOVO NORDISK A/S65.08%245 091
ELI LILLY AND COMPANY45.45%223 321